Journal of Clinical Oncology
Articles in this Issue
Optimization of immunotherapy duration for advanced melanoma: The prospective OTIMAS trial.
1608 Background: Anti-PD1 monotherapy is a common option for first-line treatment for advanced melanoma in resource-constr...
Genomic landscape of <i>KRAS</i> mutations: A retrospective clinico-genomic database analysis.
e15085 Background: Since the approval of KRAS G12C inhibitors, there is ongoing interest in trials for combination treatme...
Treatment outcomes for non-metastatic colorectal cancer in Nigeria: A 10-year retrospective study.
e15655 Background: Although the role of chemotherapy in the treatment of non-metastatic colorectal cancer (CRC) has been e...
NEO-ERA-01(CLEAP2507): A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.
e16295 Background: The high recurrence rate after resection compromises survival in patients with resectable intrahepatic...
NRG-GY037: A phase III randomized trial of induction chemotherapy and pembrolizumab followed by chemoradiation and pembrolizumab maintenance versus standard chemoradiation and pembrolizumab maintenance in high-risk locally advanced cervical cancer.
TPS5632 Background: Concurrent chemoradiation therapy (CCRT) is the standard of care for locally advanced cervical cancer...
Influence of precision treatment with artificial intelligence–assisted subtyping on first-line therapeutic efficacy in HR+/HER2– breast cancer.
e13054 Background: The combination of CDK4/6 inhibitors and endocrine therapy (ET) has become the first-line standard trea...
A targeted phosphoproteomic assay to enable the prediction of response to intensive chemotherapy in acute myeloid leukemia.
6521 Background: Intensive chemotherapy (IC; cytarabine plus an anthracycline) remains a standard first-line therapy for f...
Immunohistochemical profile and age distribution of breast cancer at a tertiary referral center in Abuja, Nigeria: A two-year retrospective study.
e13116 Background: Breast cancer outcomes in sub-Saharan Africa are often poor, driven by late presentation and aggressive...
Improving immunotherapy response with direct-acting antiviral therapy in patients with advanced hepatocellular carcinoma and chronic hepatitis C virus infection.
e16181 Background: Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) carries a poor prognosis. Immune checkpo...
Adaptive targeting of lung cancer using the anti-P329G adapter CAR T-cell platform.
e14514 Background: Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic malignancie...
Twenty years of metastatic uveal melanoma management: Real-world experience from a comprehensive cancer center in a low- and middle-income country (LMIC).
9545 Background: Uveal melanoma (UM) is a rare malignancy arising from melanocytes of the uveal tract and accounts for 85%...
Comprehensive plasma-based epigenomic profiling from INTR@PID Lung 037 study samples to identify pathways associated with response and resistance to pembrolizumab in PD-L1–high NSCLC.
e20547 Background: Pembrolizumab produces variable benefit in PD-L1-high metastatic NSCLC, and mechanisms of resistance re...
Real-world outcomes of neoadjuvant concurrent chemoradiotherapy with epirubicin–ifosfamide in localized high-grade soft tissue sarcoma: A single-center retrospective series (N=57).
e23547 Background: Neoadjuvant chemotherapy combined with radiotherapy (nCRT) is an established strategy for selected pati...
Real-world outcomes and cross-resistance of sequential antibody-drug conjugate therapy in HER2-low and triple-negative breast cancer: A systematic review.
e12548 Background: Antibody–drug conjugates (ADCs) have demonstrated superior efficacy over chemotherapy in HER2-low and t...
Reducing effort through informatics-driven identification, recruitment, and data capture on a trial to improve adjuvant endocrine therapy adherence.
11025 Background: Adjuvant endocrine therapy (AET) improves outcomes in HR+ breast cancer. Nonadherence to AET is common,...
A phase I/IIa dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety and preliminary efficacy of tri-specific antibody (SOA101) in subjects with advanced solid tumors.
TPS2671 Background: SOA101 is a nanobody (VHH)-based tri-specific T cell engager targeting programmed death-ligand 1 (PD-L...
Two decades of change: Trends and disparities in breast cancer surgical outcomes.
e12742 Background: Breast cancer is the most commonly diagnosed malignancy among women in the United States, and surgery r...
Clinical outcomes of patients with cell cycle alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
3149 Background: Cell cycle pathway alterations are a hallmark of cancer. Disruption of cell cycle checkpoints results in...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.
6592 Background: Recent preclinical and clinical evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 R...
Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma.
7087 Background: Exposure to opioids during cancer treatment is common and may lead to new persistent opioid use (NPOU) in...
A randomized, double-blind, placebo-controlled pilot study of add-on beta-sitosterol supplementation on treatment response in metastatic prostate cancer patients.
e17073 Background: Metastatic prostate cancer remains difficult to manage due to treatment resistance and cumulative toxic...
Addressing health-related social needs for cancer patients: An implementation assessment.
1575 Background: Health-related social needs (HRSNs) are associated with delayed diagnosis and treatment, worsened quality...
Palliative care utilization in metastatic lung cancer at an urban safety-net hospital.
e20651 Background: Early integration of palliative care has been associated with improved survival, quality of life, and r...
Real-world clinicopathologic characteristics and outcomes of MSI-high colon cancer in community oncology practice from western India.
e15585 Background: Microsatellite instability–high (MSI-H) colon cancer represents a distinct molecular subset with progno...
Physician preferences for metastatic hormone-sensitive prostate cancer treatment: A discrete choice experiment in China.
e17086 Background: Androgen receptor pathway inhibitors (ARPIs) improve disease control and overall survival (OS) in metas...